Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00233402 · ClinicalTrials.gov registry record · Phase 3
Study to Improve Detection and Early Recurrence Rate in Bladder Cancer Patients Using Hexvix Fluorescence Cystoscopy
A Phase 3 study, sponsored by Photocure.
- Completed
- Registry status
- Phase 3
- Development phase
- 789
- Enrollment target
NCT00233402: Completed Phase 3 study, sponsored by Photocure.
NCT00233402 is a Phase 3 study that has completed, run by Photocure. The registered enrollment target is 789 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00233402, a Phase 3 study, has completed, sponsored by Photocure.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 789 participants
- Enrollment target
Study Summary
The purpose of this study is to document the additional detection of papillary bladder cancer and the reduced early recurrence due to the improved detection and resection of these tumors after Hexvix cystoscopy compared to standard cystoscopy in patients with papillary bladder cancer.
Interventions
- DRUG Hexvix
- PROCEDURE Standard white light cystoscopy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 789 participants |
| Start Date | 2005-01 |
| Est. Completion | 2008-08 |
| Phase | Phase 3 |
What the finished NCT00233402 record still lists
NCT00233402 is an interventional study that assigns participants to a tested intervention. The registered 789 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Hexvix is the first listed.
NCT00233402 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00233402 about?
NCT00233402 is a clinical study titled "Study to Improve Detection and Early Recurrence Rate in Bladder Cancer Patients Using Hexvix Fluorescence Cystoscopy". The purpose of this study is to document the additional detection of papillary bladder cancer and the reduced early recurrence due to the improved detection and resection of these tumors after Hexvix cystoscopy compared to standard cystoscopy in patients with papillary bladder cancer.
What is the current status of trial NCT00233402?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 789 participants. The study started on 2005-01. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00233402?
The interventions under investigation include: Hexvix (DRUG), Standard white light cystoscopy (PROCEDURE).
Who is sponsoring clinical trial NCT00233402?
This trial is sponsored by Photocure, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00233402's enrollment target sits among peer trials
789 431st of 2000 higher than 1,570 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04967989 · 790 participants · Phase 3
Clarifying the Optimal Application of SLT Therapy Trial
- NCT06162611 · 790 participants · Phase 4
Etonogestrel (ENG) Implant Insertion for Emergency Contraception With Oral Levonorgestrel (LNG) vs Placebo
- NCT06488781 · 787 participants · Phase 2
Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term 2.0
- NCT06876649 · 787 participants · Phase 4
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia